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Abstract: Oral candidiasis is a common side effect of cancer chemotherapy. To better understand
predisposing factors, we followed forty-five subjects who received 5-fluorouracil- or doxorubicin-based
treatment, during one chemotherapy cycle. Subjects were evaluated at baseline, prior to the first
infusion, and at three additional visits within a two-week window. We assessed the demographic,
medical and oral health parameters, neutrophil surveillance, and characterized the salivary bacteriome
and mycobiome communities through amplicon high throughput sequencing. Twenty percent of all
subjects developed oral candidiasis. Using multivariate statistics, we identified smoking, amount
of dental plaque, low bacteriome and mycobiome alpha-diversity, and the proportions of specific
bacterial and fungal taxa as baseline predictors of oral candidiasis development during the treatment
cycle. All subjects who developed oral candidiasis had baseline microbiome communities dominated
by Candida and enriched in aciduric bacteria. Longitudinally, oral candidiasis was associated with a
decrease in salivary flow prior to lesion development, and occurred simultaneously or before oral
mucositis. Candidiasis was also longitudinally associated with a decrease in peripheral neutrophils
but increased the neutrophil killing capacity of Candida albicans. Oral candidiasis was not found to
be associated with mycobiome structure shifts during the cycle but was the result of an increase in
Candida load, with C. albicans and Candida dubliniensis being the most abundant species comprising
the salivary mycobiome of the affected subjects. In conclusion, we identified a set of clinical and
microbiome baseline factors associated with susceptibility to oral candidiasis, which might be useful
tools in identifying at risk individuals, prior to chemotherapy.
Keywords: oral candidiasis; microbiome; cancer chemotherapy; risk factors
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1. Introduction
Cancer chemotherapy is associated with comorbidities, with the oral cavity representing one
of the most severely affected body sites. Oral complications include mucositis, which presents as
erythema or ulceration of the non-keratinized mucosa, and oral candidiasis, which commonly presents
as white, detachable, pseudomembranous mucosal lesions [1–3]. Oral candidiasis incidence is 20–40%
in chemotherapy recipients, depending on dose, duration, and regimen type [3]. In patients with
hematologic malignancies who are treated aggressively with a high dose of cytotoxic chemotherapy,
the incidence of oral candidiasis is higher and the consequences from this infection are more severe
than in patients receiving low-dose chemotherapeutic regimens. In addition to burning pain and taste
changes that compromise nutrition, a serious consequence of oral candidiasis in that the population is
an increased risk to lethal, disseminated infection [4–7]. A previous large-scale retrospective study
of hematologic cancer patients identified more intensive chemotherapy and longer lasting severe
leukopenia as clinical parameters increasing the risk of oral and systemic candidiasis. Importantly, in
this large cohort, almost all patients who developed oral candidiasis later developed fatal, systemic
candidiasis [7]. Despite important advances in managing chemotherapy patients with oral and systemic
fungal infections over the past three decades, these infections remain a significant clinical problem
in this population [8,9]. Thus, the identification of risk factors for oral infection is of paramount
importance in patients undergoing chemotherapy. Prospective, longitudinal studies with newer cancer
chemotherapy regimens are needed to identify the underlying factors of increased susceptibility to
oral candidiasis.
Resistance to opportunistic infections in the oral cavity is the result of a balanced interaction
between a complex oral microbiome and the host’s protective defenses. The oral microbiome is a
diverse community with hundreds of bacterial and fungal taxa [10–12]. These communities live in
constant cross-talk with the adjacent oral mucosa, eliciting the production of antimicrobial peptides
and recruitment of leukocytes that contribute to the maintenance of the microbiota, in a commensal
state [13–15]. Since not all patients subjected to a similar chemotherapy regimen develop oral
candidiasis, it is likely that inter-subject variability in the oral microbiome is related to susceptibility,
with specific fungal and bacterial microbiome profiles setting the stage for infection.
Chemotherapy is also associated with myelosuppression, with severe long-lasting neutropenia or
alterations in neutrophil chemotaxis placing patients at risk of systemic candidiasis [16,17]. In vitro
assays suggest that chemotherapeutics affect neutrophil function [18]. Neutrophils offer protection
from the oral overgrowth of Candida albicans [19]—the fungus most frequently associated with oral
candidiasis [20]. Thus, decreased neutrophil oral availability and alterations in neutrophil function
as a consequence of chemotherapy, combined with mucosal injury might affect oral candidiasis risk.
Moreover, a decrease in salivary flow rate (SFR), reported to occur during chemotherapy [21], could
lead to an impaired delivery of candidacidal antimicrobials [22], predisposing to oral candidiasis.
Other chemotherapy-associated treatments such as antibiotics, could affect the oral microbiome
predisposing to Candida overgrowth. At non-oral mucosal barriers, antibiotic perturbation of resident
bacteria has been linked to candidiasis [23], but it is less clear if antibiotic intake confers a risk in the
oral cavity. Instead, C. albicans and certain oral commensal bacteria have been suggested to have a
synergistic relationship [24,25] and a recent mouse model of chemotherapy-associated candidiasis
has provided direct evidence to support this concept [26]. Delineation of factors that predispose
individuals undergoing chemotherapy to oral candidiasis, could lead to clinical tools for the application
of preventive approaches, based on individual risk.
Accordingly, this study investigated the factors associated with the development of oral candidiasis
during chemotherapy. Forty-five patients undergoing 5-fluorouracil (5-FU)- or doxorubicin-based
chemotherapy were evaluated at 4 time-points during one chemotherapy cycle, including a baseline
visit prior to the first infusion and three subsequent visits within a two week window. The variables
evaluated included the demographic, medical, and oral clinical characteristics of subjects, together with
an assessment of neutrophil surveillance, bacterial and Candida burdens, and the oral bacteriome and
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mycobiome. Our goal was to identify patient characteristics related to oral candidiasis susceptibility in
this clinical setting.
2. Materials and Methods
2.1. Study Design
This observational prospective study was approved by the Institutional Review Board at UConn
Health (IRB number IE-11-037J-2) and conformed with the rules of the Declaration of Helsinki of 1975
(https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/), as revised in 2013, and
with STROBE guidelines. Subjects treated for a solid tumor—with either a 5-fluorouracil (5-FU)- or a
doxorubicin (Adriamycin)-based chemotherapy regimen—were recruited at the Neag Comprehensive
Cancer Center of UConn Health and at the Helen and Harry Gray Cancer Center at Hartford Hospital.
Subjects were seen at four visits, which included a baseline visit completed prior to subjects commencing
chemotherapy. The day of the first infusion was considered day 0, after which subjects were evaluated
at three additional visits at days +3 (±2), +9 (±2), and +14 (±2). A detailed characterization of this
study cohort, with respect to the development of oral mucositis, has been previously published by our
group [27]. Our previous report included 49 subjects. In the current study, 45 subjects were included
in the analyses as 4 subjects did not have complete clinical oral evaluations to assess oral candidiasis at
all visits.
2.2. Demographic and Medical Data Collection and Oral Evaluation
Medical information was obtained from questionnaires and medical charts. All subjects received an
oral evaluation at baseline, including an assessment of the presence of periodontitis, via the Community
Periodontal Index of Treatment Needs (CPITN) [28], presence and type of prosthetic restorations,
number of teeth, and presence of visible cavitated carious lesions. In addition, the following data were
collected at all visits—presence of oral candidiasis defined as detachable pseudomembranous white
lesions on the oral mucosa; unstimulated SFR; and amount of plaque on teeth, as determined via the
Plaque Index of Silness and Löe [29].
2.3. Saliva Collection
At each visit, unstimulated saliva was collected to determine SFR and for microbiome evaluation.
Participants were instructed to avoid eating or drinking anything other than water, for one hour prior
to each study visit. Unstimulated saliva was collected for 5 min by having subjects lean forward over a
sterile funnel attached to a vial placed in ice. Saliva was weighted to determine the salivary flow rate,
and then aliquoted and centrifuged at 2200 g for 10 min. Supernatants were removed and pellets were
stored at −80 ◦C.
2.4. Evaluation of Peripheral Blood and Oral Neutrophil Counts
Total counts and percentages of neutrophils were obtained from the complete blood counts
performed by the hospital laboratory, using an automated Beckman Coulter analyzer. Oral cells were
collected at all study visits by asking subjects to rinse with 10 mL of a bicarbonate solution for 30 s.
Oral rinse samples were centrifuged at 1258× g for 15 min and the pellets were resuspended in Hanks’
Balanced Salt solution, supplemented with 2 µg/mL acridine orange. Granulocytes, characteristically
stained as multilobulated cells with this nuclear stain, were counted in a hemacytometer, under a
fluorescence microscope [30].
2.5. Evaluation of Peripheral Neutrophil Killing of C. albicans
At baseline and visit 4, 50 mL of blood were collected from a convenience subset of patients (n = 14)
and neutrophils were isolated from the anticoagulated blood by dextran T-500 sedimentation, followed
by density gradient centrifugation and erythrocytic lysis, through hypotonic shock. Cells were washed
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with Hank’s Balanced Salts Solution without calcium and magnesium, and were re-suspended in RPMI
1640 with 10 mM HEPES (Mediatech, Inc.). The resulting cell preparations consisted of more than
95% neutrophils, as assessed by the Wright–Giemsa stain and more than 98% were viable by trypan
blue exclusion. The antimicrobial effector function of these cells was tested against C. albicans SC5314.
Neutrophils were added to C. albicans at effector:target ratios ranging from 5:1 to 1:1. After incubation
at 37 ◦C and 5% CO2 for 2 h, media were aspirated and neutrophils were lysed with sterile water. This
was followed by quantification of metabolically active C. albicans via the XTT assay. Antifungal activity
was calculated according to the following formula: % fungal damage = (1 − x/n) * 100, where x is
the OD450 absorbance of experimental wells (C. albicans with effectors) and n is the absorbance of the
control wells (C. albicans only) [31].
2.6. DNA Extraction and Generation of 16S rRNA Gene and ITS-1 DNA Libraries
DNA was extracted from saliva samples, separately for bacterial and fungal microbiome evaluation.
For bacteria, we followed a previously described procedure using lysozyme and proteinase K treatment
and the DNeasy Blood and Tissue kit (Qiagen) [32]. For fungi, the DNA extraction protocol involved
bead beating with a matrix containing Lysing Matrix B (MP Biomedicals) and a very high density
0.5 mm yttrium-stabilized zirconium oxide (95% ZrO2 + 5% Y2O3) grinding media (YSZ) (Glen Mills Inc,
Clifton, NJ, USA), followed by extraction using the FastDNA SPIN KIT (MP Biomedicals), as previously
described [12]. Amplicon libraries of the 16S rRNA gene V1–V2 hypervariable regions were generated in
triplicates, using fusion primers, which included universal primers 8F AGAGTTTGATCMTGGCTCAG
or 361R CYIACTGCTGCCTCCCGTAG [33]. PCR conditions have been previously described [32]. For
mycobiome characterization, fusion primers containing fungal-specific ITS1F forward primer [34]
(CTTGGTCATTTAGAGGAAGTAA) or ITS2 reverse primer [35] (GCTGCGTTCTTCATCGATGC) were
used to amplify the ITS1 sequences, in triplicates, as previously described [12]. The combined libraries
were further purified and sequenced using 454 Titanium chemistry and the 454-GS-FLX sequencing
platform (454 Life Sciences, Branford, CT).
2.7. Processing of Amplicon Sequences and Taxonomic Classification
16S rRNA gene reads were processed in mothur [36]. Primers and barcodes were trimmed,
followed by the removal of sequences shorter than 200 bp, with homopolymers greater than eight
nucleotides or ambiguous base calls. Sequences were then filtered using a 50 bp sliding window
approach and an average quality score threshold of 35 [37]. Chimeric sequences were removed with
UChime [38], in mothur. Sequences were then classified to the species level, by using the classify.seqs
command and the Human Oral Microbiome database (HOMD) V14.5 as reference. The parameters
used were—method = knn, search = blast, gapopen = −5, gapextend = −5, match = 4, mismatch = −5,
and numwanted = 1, following recommendations by Al-Hebshi et al. [39]. This taxonomy assignment
algorithm was validated by classifying the HOMD reference sequences, trimmed to include only the
V1–V2 region, against the HOMD full length reference sequence database. With a few exceptions, all
V1–V2 short sequences were correctly classified in the validation test. However, the following species
could not be discriminated from each other—Lactobacillus casei and Lactobacillus rhamnosus; Veillonella
parvula and Veillonella dispar; Streptococcus mitis, Streptococcus pneumoniae and Streptococcus sp. HOT423;
and Neisseria flavescens and Neisseria subflava. Counts for species that could not be correctly identified
were aggregated.
ITS-1 reads were also processed in mothur [36]. Sequences were trimmed, quality filtered,
and chimeras removed, as described for 16S rRNA sequences. Sequences were then classified
to genus level by using the classify.seqs command and a modified version of the Findley et al.
database [40] as a reference, employing the recommended parameters (https://www.mothur.org/
wiki/Findley_ITS_Database). Prior to this, a curation of the Findley et al. database was conducted
to join the synonym taxa under one preferred name [20]. To accomplish this, reference sequences
from synonym taxa were compared via BLAST against NCBI’s nucleotide type strain database and
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against the Fungal Metagenomics Project database. After confirming their genus identity, Gueomyces
sequences were included under Trichosporon; Lewia under Alternaria; Valsa under Cytospora; Coprinellus
and Coprinopsis under Coprinus; Erythrobasidium under Rhodotorula; Cochliobolus under Curvularia;
Filobasidium, Cystofilobasidium and Dioszegia under Cryptococcus; and Emericella under Aspergillus.
In addition, sequences of Cladosporium, Toxicocladosporium, Aureobasidium, Kabatiella, Scleroconidioma
and Candida were added as they were underrepresented in the database. Malassezia and Candida ITS-1
sequences were further classified to the species level, using curated and aligned reference libraries
and the software package pplacer [41], as previously described [40]. All sequences are available at the
Short Reads Archive (Accession number PRJNA399163).
2.8. Alpha-Diversity Estimates for 16S rRNA gene and ITS-1 Amplicon Data
16S rRNA gene libraries were subsampled at 3074 reads and ITS-1 at 1338 reads, a threshold which
was shown to yield sufficient depth, maximizing the number of samples included in the analysis [27].
Community alpha-diversity was evaluated via the non-parametric Shannon Index, as calculated in
mothur. These metrics were constructed, based on the species-level taxonomic units for 16S rRNA gene
reads and the genus-level for ITS-1 (with the exception of Malassezia and Candida that were speciated).
2.9. Evaluation of Salivary Bacterial and Candida Load via Real Time PCR
Total bacterial load in the saliva was measured via real-time PCR, using a TaqMan®probe and
universal 16S rRNA gene primers, as previously described [42]. A standard curve, generated with
serially-diluted genomic DNA from Fusobacterium nucleatum was used a reference. For quantification
of the Candida load, we used Candida-specific ITS primers and SYBR Green (Roche) detection, as
described [43]. A standard curve generated with genomic DNA obtained from serially diluted
C. albicans SC5314 cells was used as a reference.
2.10. Statistical Analyses
Baseline nominal data were compared between the oral candidiasis-positive and negative subjects
by Fisher’s exact test, and categorical data were compared via chi-square. Continuous data were
evaluated via independent sample t-tests or Mann–Whitney U tests, according to the data distribution.
The distribution of continuous data was tested for normality, using measures of Skewness and Kurtosis
and the Shapiro–Wilk test in SPSS. Differences in the intake of medications during the cycle, according
to the oral candidiasis incidence, were evaluated via Fisher’s exact tests.
To evaluate the discriminant, demographic, clinical, or microbial baseline characteristics that
could classify subjects that developed oral candidiasis during the cycle and the unaffected individuals,
we performed sparse Partial Least Squares discriminant analysis (sPLS-DA) using the R package
MixOmics [44]. Prior to this analysis, microbiome relative abundance data were filtered to exclude taxa
present in less than 10% of baseline samples and data were transformed using a Centered Log Ratio
transformation procedure [45]. The classification performance of the PLS-DA model was assessed with
the perf function, using five-fold cross-validation, repeated ten times. Differences in the individual
baseline proportions of identified discriminant taxa between affected and unaffected subjects, were
also evaluated via Mann–Whitney Rank tests.
Longitudinal data were evaluated in subject-matched samples. Differences in subject-matched
longitudinal data were evaluated via paired Wilcoxon Rank tests. We were also interested in the
longitudinal changes in the presence of oral candidiasis signs and the relationship of these changes
with other variables. We, therefore, modelled the change in each longitudinal variable across four visits,
using linear or quadratic orthogonal polynomial contrasts. For this, each data point was multiplied by
a standard coefficient (for a linear or quadratic four level contrast) and data were aggregated by subject.
Correlations between linear or quadratic longitudinal change and other variables were determined
via Spearman Rank tests and the significance threshold was adjusted using the Benjamini Hochberg
false discovery rate method. Evaluation of the longitudinal covariation in microbial abundances and
J. Fungi 2019, 5, 49 6 of 21
clinical parameters measured at the four visits of the study was performed using MixOmics. For this
analysis, we used the multilevel function and compared microbial and clinical variables, using sparse
Partial Least Squares (sPLS) regression. This multilevel multivariate approach takes into account the
repeated measures within subjects and the use of sPLS reveals covariation patterns in all variables in
an unsupervised manner.
3. Results
3.1. Evaluation of Baseline Characteristics Associated with Oral Candidiasis Incidence during a
Chemotherapy Cycle
The characteristics of the subjects included in this study are summarized in Tables 1 and 2. Of the
45 subjects receiving chemotherapy, 9 (20%) developed oral candidiasis during the cycle (Table 1). Our
first goal was to identify factors at baseline, related to the development of oral candidiasis. Table 1
compares the demographic, medical, and oral clinical characteristics of patients at baseline, between
subjects that developed oral candidiasis and those that remained candidiasis-free. No demographic
variable was associated with oral candidiasis. Among the general characteristics evaluated, only
smoking showed an association with oral candidiasis, with a greater percentage of current smokers
and subjects with a smoking history in the candidiasis-positive group. Baseline salivary flow rate,
which might be important for oral mucosal defenses [46], did not differ between groups.
Since neutrophil surveillance has been linked to the control of C. albicans growth and
dissemination [19,47], we conducted a baseline evaluation of the number of neutrophils in peripheral
blood and saliva and the ability of neutrophils to kill C. albicans in a laboratory in vitro assay (Table 1).
The number of baseline peripheral (but not oral) neutrophils was higher in the subjects that later
developed oral candidiasis. The causes for this difference were not clear, as a higher baseline number of
neutrophils in the candidiasis-positive group was not related to the frequency of steroid premedication,
prior to chemotherapy, a known inducer of neutrophilia [48] (Table 1). Despite differences in peripheral
neutrophils at baseline, the number of oral neutrophils and their ability to kill C. albicans at this visit
did not differ among oral candidiasis-positive and unaffected individuals.
Next, we checked if baseline, oral, microbiome-related characteristics of subjects were associated
with the development of oral candidiasis. The plaque index, a measurement of the amount of
visible dental plaque was significantly different between oral candidiasis-positive and negative
subjects with a higher baseline plaque index in subjects that later developed oral candidiasis (Table 1).
We also measured the salivary bacterial and Candida load via qPCR assays and characterized the
bacteriome and mycobiome via high throughput sequencing of the 16S rRNA gene and the ITS1
region, respectively. As seen in Table 1, baseline salivary bacterial and Candida load did not differ
between oral-candidiasis-positive and oral-candidiasis-negative subjects. However, the bacteriome
and mycobiome alpha-diversity was lower in subjects that later developed oral candidiasis, suggesting
that certain oral microbiome communities are associated with a higher risk of developing the disease.
We found that bacteriome communities were highly diverse, contrary to mycobiome communities
which were dominated by two main genera—Candida and Malassezia. The percentage of these genera
in baseline saliva samples was different between subjects that developed oral candidiasis and those
that remained candidiasis-free, with all subjects that developed the disease showing mycobiome
communities dominated by Candida (83.2–99.9% of all fungal reads), and near absence or low proportions
of Malassezia (Table 1).
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Table 1. Baseline characteristics of the study subjects according to the oral candidiasis diagnosis during
the chemotherapy cycle. All data represent information collected or measurements taken at baseline,
prior to the chemotherapy cycle.
Variable No Candidiasisn = 36
Oral Candidiasis
n = 9 Statistic
Age 57.9 ± 13.6 56.6 ± 10.8 0.788 *
Gender (% male) 50.0 77.8 0.260 @
Race (% white) 86.1 100.0 0.566 @
Ethnicity (% hispanic) 5.6 0.0 1.000 @
Squamous-cell carcinoma (% yes) 36.1 66.7 0.137 @
Breast cancer (% yes) 33.3 11.1 0.248 @
Adenocarcinoma (% yes) 25.0 11.1 0.659 @
Other cancer (% yes) 5.6 11.1 0.497 @
Smoking history (% yes) 58.3 100.0 0.020 @
Former smoker (% yes) 55.6 33.3 0.284 @
Current smoker (% yes) 2.8 66.7 0.00007 @
Proton pump inhibitor use (% yes) 27.8 11.1 0.416 @
Inhaler steroid use (% yes) 2.8 11.1 0.364 @
Steroid premedication prior to V1 (% yes) 16.7 22.2 0.651 @
Number of teeth 26 (0–32) 21 (0–28) 0.190 &
Prosthetic teeth (% yes) 77.8 77.8 1.000 @
Number of teeth replaced by prosthesis 2 (0–25) 2 (0–32) 0.967 &
Removable prosthesis (% yes) 13.9 11.1 1.000 @
Visible caries lesions (% yes) 30.6 44.4 0.454 @
Number of teeth with caries lesions 0.81 ± 1.5 2.56 ± 3.7 0.200 *
Plaque index 0.9 (0.0–2.1) 1.8 (1.0–2.5) 0.001 &
Periodontal status (CPITN, %)
Healthy
Bleeding
Calculus or defective restorations
Periodontal pocket between 4 and 5 mm















Salivary flow rate (mL/min) 0.39 (0.06–0.93) 0.42 (0.05–1.46) 0.625 &
Peripheral absolute neutrophil count
(× 1000/mm3 blood) 5.4 (2.2–16.1) 12.1 (3.1–18.4) 0.039
&
Oral neutrophil count (× 10,000/rinse) 44 (6–473) 24 (6–143) 0.309 &
C. albicans killing by peripheral neutrophils
(% killed C. albicans) n = 14 subjectsˆ 62.2 (30–82) 53.5 (30–76) 0.240
&
Bacterial load (16S rRNA copies/mL saliva) 4.9E+09 ± 4.8E+09 2.0E+09 ± 2.1E+09 0.104 *
Candida load (Candida cells/mL saliva) 2.5E+03 ± 2.1E+03 5.2E+03 ± 9.0E+03 0.399 *
Salivary bacterial diversity (16S rRNA
gene based—np Shannon Index) 3.2 ± 0.31 2.6 ± 0.40 0.0001 *
Salivary fungal diversity (ITS1
based—np Shannon Index) 0.99 ± 0.81 0.14 ± 0.17 0.00001 *
Percentage Candida 27.7 (0.0–99.6) 98.7 (83.2–99.9) 0.0005 &
Percentage Malassezia 16.0 (0.0–98.4) 0.1 (0–15.6) 0.0007 &
The distribution of continuous data was tested for normality, using measures of Skewness and Kurtosis and the
Shapiro–Wilk test in SPSS. For the normally-distributed continuous variables, mean ± standard deviation is shown.
For the non-normally distributed continuous variables, median is shown, with the range in parentheses. Statistical
tests for continuous data were applied according to the data distribution. For non-continuous variables, the data
shown represent the percentage of subjects that tested positive. ˆ Of the 14 subjects included in the C. albicans killing
assays, 9 did not present oral candidiasis during the cycle and 5 developed oral candidiasis. # chi-square; @ Fisher’s
exact test; & Mann–Whitney U test; * Independent sample t-test. Variables that differed between candidiasis-positive
subjects and unaffected individuals are shown in bold.
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3.2. Multivariate Analysis of Baseline Demographic, Medical, Oral, Neutrophil, and Microbiome
Characteristics That Discriminated Between Oral-Candidiasis-Positive and Oral-Candidiasis-Negative Subjects
Next, we used sparse partial least square discriminant analysis (sPLS-DA), which enabled the
selection of the most predictive or discriminative features in a dataset [44], for a multivariate analysis
of the baseline characteristics that could best separate subjects who developed oral candidiasis, from
the unaffected individuals. The model presented in Figure 1A, which had a cross-validated the
overall classification error rate of ~15%, separated the subjects into two clusters, according to the oral
candidiasis diagnosis. Figure 1B shows the variables driving the separation along component 1, the
main component discriminating candidiasis-positive and candidiasis-negative subjects. Being a current
smoker and having a high Plaque Index were the baseline clinical characteristics contributing to a shift
towards the positive side of component 1 and were, therefore, associated with the development of oral
candidiasis. Alongside these variables, higher baseline proportions of several species of Lactobacillus,
Streptococcus parasanguinis II, Veillonella dispar/parvula, and Streptococcus mutans, among others, were also
associated with oral candidiasis (Figure 1B). The baseline levels of Candida, in particular C. albicans, were
the only mycobiome features associated with oral candidiasis (Figure 1B). However, it is worth noting
that the effect of some bacteriome members was greater than the effect of the baseline proportions
of Candida. In contrast, having baseline salivary bacteriome and mycobiome communities of higher
diversity, higher baseline levels of bacteria such as Porphyromonas sp. HOT 279, Streptococcus australis,
Haemophilus parainfluenzae, and Catonella morbi, among others, and higher baseline proportions of
fungi such as unclassified Saccharomycetaceae and Malassezia, were negatively associated with the
development of oral candidiasis (Figure 1B). Figure 1C,D show the baseline proportions of the bacterial
and fungal taxa identified in the sPLS-DA analysis as discriminating between candidiasis-positive and
unaffected individuals. In conclusion, although only twenty percent of the subjects were positive for
oral candidiasis, it was still possible to develop a multivariate model of baseline factors associated
with the infection. This model pointed to smoking, amount of visible plaque, low bacteriome and
mycobiome diversity, and specific bacteriome and mycobiome components as risk factors for the
development of oral candidiasis during chemotherapy.




  Figure 1. Multivariate sparse partial least square discriminant analysis (sPLS-DA) to identify baseline
variables that are able to differentiate subjects that later developed oral candidiasis during chemotherapy
(n = 9) from those that remained candidiasis-free (n = 36). (A) Separation of subjects that tested positive
and negative for oral candidiasis, according to the sPLS-DA model. (B) Variables with their loadings
contributing to component 1, which best separated subjects based on an oral candidiasis diagnosis. All
baseline variables measured were taken into account in the analysis, including demographic, medical,
oral-health, and neutrophil characteristics, bacterial and Candida burdens, microbiome diversity, and
the proportions of microbiome taxa present in at least 10% of subjects. (C) The baseline proportions of
bacterial (1st row) and fungal (2nd row) taxa, identified in the sPLS-DA model as ‘increased’ in subjects
that later developed oral candidiasis. (D) The baseline proportions of bacterial (1st row) and fungal
(2nd row) taxa, identified by the sPLS-DA model as ‘increased’ in the unaffected subjects. p values
(unadjusted) shown in C and D are those that were significant after comparing the proportions via
Mann–Whitney rank tests.
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3.3. Characterization of Clinical Factors Associated With the Longitudinal Progression of Oral Candidiasis
during Chemotherapy
Next, we conducted an analysis of variables evaluated longitudinally by assessing their covariation
with the development of clinical signs of oral candidiasis. As seen in Figure 2A, the highest
number of subjects affected by oral candidiasis was seen at V3 (9 ± 2 days after chemotherapy).
Table 2 shows the medications that the subjects received during the chemotherapy cycle. There was
no relationship between receiving specific chemotherapeutic drugs or combination regimens and
developing oral candidiasis. Importantly, receiving single or multi-dose systemic antibiotics was
not associated with the development of candidiasis. Additionally, there was no association of any
type of concomitant medication, including steroids, antibiotics or proton pump inhibitors, with oral
candidiasis. As expected, receiving an antifungal, during chemotherapy, had a positive relationship
with an oral candidiasis diagnosis.
To evaluate which variables—measured at multiple time points—correlated with the development
of oral candidiasis, we modelled change over four visits with linear or quadratic polynomial contrasts.
These contrasts represent the shape of the curve that each variable followed, in each subject, during the
cycle. All subjects were included in this analysis and we used these contrasts to evaluate the correlation
between curves followed by oral candidiasis and other metadata. Results from this analysis are shown
in Table 3. A negative quadratic change in oral candidiasis (representing a down, up, down curve,
which are subjects in which candidiasis was resolved by V4) correlated with a positive linear change in
oral mucositis. This suggests that oral mucositis (erythema or ulcerations) occurred concomitantly,
with or after a diagnosis of oral candidiasis, in patients that developed both conditions. With respect to
changes in saliva availability, there was no difference in SFR at the visit with oral candidiasis, compared
to baseline (Figure 2B). However, when we modelled the change in SFR in relation to oral candidiasis
(Table 3), there was a correlation between having a decreased SFR in the middle of the cycle (positive
quadratic curve—up, down, and up) and a linear increase in oral candidiasis, which suggested that
decreased SFR preceded candidiasis clinical signs.




n = 9 Statistic
5-FU 66.7 77.8 0.698 @
Doxorubicin 33.3 22.2 0.698 @
Docetaxel 38.9 66.7 0.157 @
Cyclophosphamide 33.3 11.1 0.249 @
Cisplatin 27.8 66.7 0.050 @
Carboplatin 16.7 11.1 1.000 @
Oxaliplatin 13.9 11.1 1.000 @
Leucovorin 16.7 11.1 1.000 @
Herceptin 2.8 11.1 0.364 @
Mitomycin 2.8 0.0 1.000 @
Bevacizumab 5.6 0.0 1.000 @
Irinotecan 2.8 0.0 1.000 @
Vinblastine 0.0 11.1 0.200 @
5FU-docetaxel-cisplatin 25.0 55.6 0.111 @
5FU-docetaxel-carboplatin 13.9 11.1 1.000 @
5FU-oxaliplatin-leucovorin 8.3 0.0 1.000 @
5FU 5.6 0.0 1.000 @
5FU-mitomycin 2.8 0.0 1.000 @
5FU-oxaliplatin-leucovorin-herceptin 2.8 11.1 0.364 @
5FU-cisplatin-carboplatin 2.8 0.0 1.000 @
5-FU-irinotecan-Bevacizumab-leucovorin 2.8 0.0 1.000 @





n = 9 Statistic
5FU-oxaliplatin-leucovorin-Bevacizumab 2.8 0.0 1.000 @
Doxorubicin-cyclophosphamide 33.3 11.1 0.249 @
Doxorubicin-cisplatin-vinblastine 0.0 11.1 0.200 @
Steroid during cycle 80.6 55.6 0.190 @
Pegfilgrastim 72.2 88.9 0.416 @
Proton pump inhibitors 66.7 77.8 0.698 @
Any antibiotic 38.9 66.7 0.157 @
Single dose prophylactic 22.2 33.3 0.666 @
Multi-dose antibiotic 19.4 33.3 0.393 @
Any antifungal 2.8 100.0 0.0000001
Nystatin 0.0 77.8 0.000001
Fluconazole 2.8 22.2 0.097
Data represent the percentage of subjects that received the medication. @ Fisher’s exact test. Variables that differed
between candidiasis positive subjects and unaffected individuals are shown in bold.
We also evaluated the relationship of blood and salivary neutrophil counts with the incidence
of oral candidiasis. A decrease in the peripheral neutrophil counts compared to the baseline, in the
same individuals, was seen at the visit when subjects presented with candidiasis (Figure 2C), and
as seen in Table 3, the negative quadratic (down, up, and down) or positive linear progression of
oral candidiasis, correlated with decreased peripheral neutrophils counts, in the middle of the cycle
(positive quadratic curve). It should be noted that peripheral neutrophils followed this pattern of
longitudinal variation in most subjects, decreasing by V3 and rebounding by V4 [27]. In contrast, oral
neutrophils did not decrease during oral candidiasis (Figure 2D) and there was no correlation between
the longitudinal change in oral neutrophil counts and candidiasis (Table 3). These findings suggest
that despite decreased peripheral neutrophils as a consequence of chemotherapy, these cells continued
to infiltrate the oral tissues, as oral candidiasis occurred.
We additionally evaluated the peripheral neutrophil function by a C. albicans killing assay. There
was no change in function in the cancer group as a whole, during chemotherapy (Figure 2E). However,
by V4 there was an increase in the killing capacity of neutrophils in subjects that experienced oral
candidiasis (Figure 2F). Indeed, change in killing capacity correlated with the quadratic negative
change (down, up, and down) in oral candidiasis (Table 3) and with increased oral Candida load
at V3 (Spearman Rank test, r = 0.577, p = 0.049). These data suggest that Candida oral overgrowth
sensitized the peripheral neutrophils. No other variable, including the intake of the granulocyte
colony-stimulating factor analog pegfilgrastim, could explain this increase in function. Taken together,
these data support a relationship between oral Candida colonization levels and functional priming of
neutrophils, against the fungus.
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cycle. * indicates a p value < 0.05, when comparing subject-matched data via Wilcoxon Rank tests. 
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Salivary flow rate (Q) 0.742 −0.278(0.058) 0.401(0.005) 
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Oral neutrophil count (Q) 0.398 −0.060(0.668) 0.057(0.703) 
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Peripheral neutrophil count (L) 0.360 −0.311(0.033) 0.521(<0.001)
C. albicans killing by peripheral neutrophils (L) ˆ 0.200 −0.614(0.015) 0.336(0.220)
Plaque Index (Q) 0.767 −0.148(0.331) 0.124(0.418)
Plaque Index (L) 0.940 −0.058(0.703) −0.166(0.274)
Salivary bacterial load (Q) 0.492 0.075(0.647) −0.215(0.182)
Salivary bacterial load (L) 0.031 −0.035(0.825) 0.031(0.842)
Salivary Candida load (Q) 0.013 0.335(0.034) −0.436(0.005)
Salivary Candida load (L) 0.405 0.297(0.053) −0.038(0.808)
Salivary bacterial diversity (Q) 0.051 −0.193(0.220) 0.100(0.527)
Salivary bacterial diversity (L) 0.009 −0.175(0.250) −0.067(0.656)
Salivary fungal diversity (Q) 0.514 0.190(0.282) 0.109(0.539)
Salivary fungal diversity (L) 0.435 −0.285(0.064) −0.097(0.529)
Antibiotics (any) (Q) 0.183 0.104(0.498) −0.084(0.584)
Antibiotics (any) (L) 0.026 −0.013(0.935) 0.167(0.273)
Multi-dose antibiotic (Q) 0.533 0.163(0.283) −0.265(0.079)
Multi-dose antibiotic (L) 0.004 0.071(0.641) 0.094(0.539)
Single-dose antibiotic (Q) 0.019 −0.038(0.806) 0.074(0.627)
Single-dose antibiotic (L) 0.710 −0.003(0.985) 0.056(0.717)
Steroids (Q) <0.001 −0.252(0.095) 0.101(0.510)
Steroids (L) <0.001 −0.118(0.439) −0.047(0.761)
Acid Inhibitors (Q) 0.001 0.201(0.186) −0.220(0.147)
Acid inhibitors (L) 0.685 0.051(0.741) 0.130(0.395)
As described in the Methods section, the longitudinal analysis of oral candidiasis development and the change in
other variables measured at more than one time-point were evaluated using linear (L) or quadratic (Q) orthogonal
polynomial contrasts. Data from each variable were transformed using either linear or quadratic four-level
coefficients, and was aggregated by subject. For quadratic change, a positive value refers to a “U”-shaped curve
(i.e., high to low to high) and negative indicates an “inverted-U”-shaped curve (i.e., low to high to low). For linear
change, a positive indicates an upward change, while a negative value indicates a downward linear change from
baseline. Values from each variable were evaluated to establish if the change differed from zero, via a t-test and were
tested for their correlation with other variables, to evaluate significant covariation patterns. Data shown in the two
columns on the right are the correlation coefficients (Spearman); p values are shown in parentheses. Significance
thresholds for each outcome variable (in columns) were adjusted for multiple comparisons, via the FDR method.
Values in red indicate correlations that were significant after FDR adjustment. Values in yellow indicate correlations
with a p value < 0.05 but not significant after FDR adjustment. ˆ C. albicans killing by peripheral neutrophils was
only evaluated in a linear manner, as the data only included two time-points (baseline and V4).
3.4. Fungal and Bacterial Microbiome Changes in Chemotherapy-Associated Oral Candidiasis
We evaluated if oral candidiasis was associated with longitudinal changes in salivary fungal
and bacterial loads. As seen in Figure 3A, the Plaque Index did not differ between baseline and the
visit when subjects presented with oral candidiasis. The salivary bacterial load showed a slight but
not statistically significant increase from baseline, in subjects with oral candidiasis (Figure 3B) and
there was no significant correlation between change over time in the bacterial load and the clinical
development of oral candidiasis (Table 3). Our cancer cohort, as a whole, did not experience significant
changes in salivary Candida biomass, over the course of the chemotherapy (Figure 3C). As expected,
there was a statistically significant increase in the Candida load, as oral candidiasis signs developed and
a decrease after the antifungal therapy (Figure 3D). Indeed, Table 3 shows that the negative quadratic
change (down, up, and down curve) in the Candida load, correlated with either the negative quadratic
or the positive linear change, in the presence of oral candidiasis clinical signs.
The diversity of salivary bacterial and fungal communities did not change significantly during
the course of oral candidiasis (Figure 3E,F) and there was no correlation between the change patterns
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in these variables and oral candidiasis development (Table 3). We also found no association between
the development of oral candidiasis and the intake of medications during the cycle that could alter the
oral microbiome or its relationship with the mucosa, including antibiotics, steroids, and acid inhibitors
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Figure 3. Changes in the bacterial and fungal burdens and community diversity during the development
of oral candidiasis. (A) Changes in Plaque Index between baseline and the first visit with candidiasis. (B)
Changes in salivary bacterial load as subjects developed oral candidiasis and after antifungal treatment.
(C) Changes in salivary Candida load in all subjects, during the chemotherapy cycle. (D–F) Changes in
Candida load, bacteriome diversity, and mycobiome diversity, as subjects developed oral candidiasis
and after antifungal treatment. *indicates a p value < 0.05, when comparing subject-matched data via
Wilcoxon Rank tests.
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Figure 4 shows the mycobiome and bacteriome composition at all visits during the cycle, in subjects
that developed oral candidiasis. At almost all time-points, irrespective of oral candidiasis clinical signs
or antifungal intake, mycobiome communities were dominated by Candida, with C. albicans and Candida
dubliniensis as the most abundant species. Two subjects also showed an increase in the proportions of
Candida glabrata by the end of the cycle (Figure 4A). In an sPLS regression analysis, to assess correlations
between the longitudinal changes in the abundance of microbial taxa during the cycle and the presence
of clinical signs of oral candidiasis, no fungal or bacterial taxon appeared as significantly correlated with
candidiasis. As seen in Figure 4B, no evident patterns of change in the bacteriome species proportions
were seen, as clinical signs of oral candidiasis developed. Taken together, these results showed that
candidiasis development was not associated with longitudinal microbiome structure shifts but was the




Figure 4. Longitudinal characterization of the oral microbiome during oral candidiasis development
and after antifungal use. Salivary mycobiome (A) and bacteriome (B) composition of individual
samples, in subjects that developed oral candidiasis during chemotherapy. The pie charts show the
relative proportions of fungal taxa or bacterial species. C = oral candidiasis; N = Nystatin intake;
F = Fluconazole intake. Only taxa present at a relative abundance of at least 1% (for fungi) and 5% (for
bacteria) in one sample are depicted individually in the pie charts. “Other” indicates the aggregated
counts of taxa not individually depicted.
4. Discussion
One of the common secondary effects of cancer chemotherapy treatment is oropharyngeal
candidiasis, a common condition affecting immunocompromised populations [3,49–51]. Older studies
in solid organ tumor cohorts used culture and biochemical phenotyping methods and identified
C. albicans, followed by C. tropicalis and C. glabrata as the most frequent species associated with this
infection (reviewed in [3]). Using next generation sequencing methods, we confirmed that C. albicans
is the main species associated with oral candidiasis, in the chemotherapy setting, but also identified
C. dubliniensis as the second most abundant species, in a subset of subjects who developed oral
candidiasis. Due to its phenotypic resemblance to C. albicans, it is possible that previous studies have
misidentified C. dubliniensis as C. albicans and underestimated its association with oral infection in
this population [52]. This might have clinical implications as oral C. dubliniensis isolates from patients
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with hematologic malignancies have been reported to develop resistance to fluconazole, a mainstream
prophylactic antifungal used in chemotherapy recipients [4]. Importantly, this is the first time a high
throughput amplicon sequencing approach was used, to longitudinally analyze the mycobiome in
subjects who developed oral candidiasis during cancer chemotherapy. Our analyses showed that the
infection was not due to the acquisition of a new fungal species or structural community changes, but
due to the increased load of species that were part of the commensal communities pre-treatment. We
found that Candida was dominant in the mycobiome of all subjects, prior to developing oral candidiasis,
and this mycobiome composition was preserved as clinical signs appeared, with candidiasis mainly
characterized by increased Candida load when clinical signs were present. This confirms the findings of
a longitudinal study that used molecular fingerprinting approaches, to follow patients with HIV-related
immunosuppression who developed oral candidiasis [53]. Importantly, antifungals were able to
decrease the Candida load but did not significantly alter the mycobiome composition, with Candida
still remaining the most abundant fungal commensal, after treatment. Antifungals, therefore, did not
modify the future risk of oral candidiasis, as conferred by a Candida-dominated baseline community.
ITS-1-based analyses in this chemotherapy cohort suggest that a Malassezia-dominated baseline
salivary mycobiome is associated with low Candida burdens and protection from oral infection. Our
group was the first to identify Malassezia as a prominent oral mycobiome member in healthy individuals,
with relative abundance ranging from 13% to 96% [12]. It is possible that the Candida and Malassezia
species have an antagonistic relationship in the oral cavity that is driven by ecologic competition for
nutritional resources. Alternatively, it is possible that Malassezia limits Candida growth by secreting
mannosidases and other glycosyl hydrolases, which damage the Candida cell wall [54]. Despite the fact
that Candida and Malassezia are dominant eukaryotic residents of the human oral cavity, nothing is
known with respect to their interactions and their potential role in preventing infection.
Prior to our study, at least four other studies showed that chemotherapy alone almost doubles oral
Candida carriage rates, compared to pre-treatment in cancer patients (reviewed by [3]). In our study,
when the entire chemotherapy population was analyzed longitudinally, there were no significant
differences in oral Candida burdens between baseline and subsequent post-treatment visits. Differences
in methodology (culture/biochemical identification in prior studies versus molecular quantification in
this study, timing and method of sampling, type of chemotherapy agents, etc.) might have contributed
to this discrepancy. However, in mice that were orally inoculated with C. albicans while receiving
5-fluorouracil, we showed that Candida burdens increased in a time-dependent fashion and peaked
when mice developed oral pseudomembranous candidiasis [26]. In this chemotherapy patient cohort,
candidiasis occurred in patients whose oral mycobiome was dominated by C. albicans pre-treatment,
whereas infection was temporally associated with a further increase in Candida burdens, consistent with
our mouse model. It should also be noted that our ITS-1-based analyses only discriminated different
species. Strain variability might also be important in determining susceptibility to oral candidiasis
and might explain why some individuals with high Candida carriage remained asymptomatic during
chemotherapy (Table 1).
A chemotherapy-induced increase in oral commensal bacterial burdens, particularly aciduric
bacteria, such as lactobacilli and streptococci, has been reported in a chemotherapy-treated human
breast cancer cohort [55]. This is in agreement with our mouse chemotherapy model where a
time-dependent increase in oral bacterial counts takes place in response to 5-FU treatment, which is
further accentuated by C. albicans infection. Similar to our mouse model, in this human cohort, oral
candidiasis was associated with a small, albeit not statistically significant, increase in oral bacterial
burdens. Interestingly, in this patient cohort, subjects who were at an increased risk for oral candidiasis
had a lower bacterial diversity and they were more abundantly colonized by aciduric bacteria including
certain Lactobacillus and Streptococcus species, prior to developing the infection, suggesting that these
bacteria might be risk factors underlying susceptibility. In particular, L. salivarius, L. oris, L. crispatus,
and S. parasanguinis, a member of the Mitis group of oral streptococci, were significantly more abundant
in patients who went on to develop oral candidiasis. Our findings suggest that when sufficiently
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abundant, these species might place this population at an increased risk for subsequent infection.
There is mounting experimental and clinical evidence (observed by our group and others) of a
pathogenic synergy or at least of a mutualistic relationship between C. albicans and the Mitis group
streptococci [25,56–58]. However, this synergy is likely to be highly species-specific within members of
this streptococcal group, since another Mitis group member (S. infantis) was less abundant in patients
who later developed oral candidiasis. Lactobacillus species have traditionally been associated with
protection from vaginal candidiasis, and several molecular mechanisms of antagonism with C. albicans
have been discovered (reviewed in [59]). With the exception of L. crispatus, there is little overlap
between the member species of the oral and vaginal mucosa, under physiological conditions [10,60].
Thus, differences in metabolic activities among Lactobacillus species abundantly colonizing the two
sites might be responsible for their opposite associations with oral and vaginal candidiasis.
In our chemotherapy cohort, oral mucositis occurred at the same time or shortly after oral
candidiasis, which suggests that mucositis does not increase risk of oral candidiasis. In agreement
with this, previous longitudinal studies in intensive chemotherapy cohorts have found no positive
risk associations between the two oral comorbidities [4,61]. However, the finding of both conditions
occurring simultaneously might have serious clinical implications, since mucositis compromises the
mucosal barrier and facilitates fungemia [62].
We found a correlation, however, between systemic myelosuppression, as evidenced by the
peripheral neutrophil counts and oral candidiasis. Despite the decreased peripheral counts, neutrophil
function (as assessed by an ex-vivo C. albicans killing assay) increased by V4, in subjects that developed
oral candidiasis at any point during the cycle or had a higher Candida load at V3. This might suggest
that, at least a subset of these cells evolved to an adaptive state that maintained a higher level of
activation, in order to protect the host. This adaptive state, known as trained innate immunity, is based
on epigenetic reprogramming and has been shown to be induced by C. albicans or fungal β-glucans, in
innate immune cells (reviewed in [63]). Furthermore, we did not observe a deficiency in oral neutrophil
numbers, which suggests that neutrophil migration into the oral tissues was still taking place. In
fact, decreased oral neutrophil availability did not correlate with oral candidiasis. Instead, other
clinical factors known to disturb local protective mechanisms were associated with oral candidiasis.
For example, a decreased salivary flow appeared to precede oral candidiasis. Other studies have
linked impaired salivary flow to increased Candida carriage [64] and oral candidiasis [65], possibly
due to a lower oral availability of Candida-controlling antimicrobial proteins. Smoking was the second
factor found to be associated with a dysregulation of local defenses and to confer an oral candidiasis
risk. The relationship between smoking and oral candidiasis is controversial, with some studies
supporting an association, while others not finding a link [65,66]. Cigarette smoke has been shown
to increase inflammatory responses of the airway epithelium [67], and smoking is associated with a
dysregulated expression of human beta defensins in oral mucosa [68]. It is possible that smoking,
in the setting of chemotherapy, becomes even more important, potentially interacting with cytotoxic
drugs to dysregulate mucosal homeostasis, facilitating Candida overgrowth and tissue damage.
This study contributes to a better understanding of the interplay between the myelosuppressive
effects of chemotherapy, the oral microbiome, and the development of oral candidiasis. We outline
novel relationships between Candida and bacterial microbiome members, which might be significant in
the pathophysiology of oral candidiasis in humans. Moreover, in an integrated analysis of baseline
clinical and microbiome characteristics associated with development of oral candidiasis, we identified
smoking, amount of visible dental plaque, low bacteriome and mycobiome alpha-diversity, and
relative abundance of specific bacterial and fungal taxa as baseline factors associated with a risk of oral
candidiasis. We presented evidence that a baseline Candida-dominated mycobiome, together with a
number of aciduric bacteria, such as oral streptococci and lactobacilli, might be important determinants
of susceptibility to this infection. Our studies represent a significant first step toward the development
of clinical and oral microbiome risk profiles, as a tool to identify immunocompromised patients that
are at a higher risk of oral candidiasis. Such tools will be instrumental in delivering well-targeted,
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patient-specific, preventive antimicrobial approaches, prior to the onset of oral infection and potential
systemic dissemination.
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